Evidence map›Paper›PMID 41538324›Full record

ArticleCell reports2026

Altered hepatic metabolism in Down syndrome.

Lauren N Dunn, Brian F Niemeyer, Neetha P Eduthan, Kyndal A Schade, Katherine A Waugh, Chrisstopher Brown, Angela L Rachubinski, Ariel E Timkovich, David J Orlicky, Matthew D Galbraith and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Lauren N DunnLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
Brian F NiemeyerLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
Neetha P EduthanLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
Kyndal A SchadeLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
Katherine A WaughLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA; Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Chrisstopher BrownLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
Angela L RachubinskiLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA; Department of Pediatrics, Section of Developmental Pediatrics, University of Colorado Anschutz, Aurora, CO 80045, USA.
Ariel E TimkovichLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA.
David J OrlickyDepartment of Pathology, University of Colorado Anschutz, Aurora, CO 80045, USA.
Matthew D GalbraithLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado Anschutz, Aurora, CO 80045, USA; RNA Bioscience Initiative, University of Colorado Anschutz, Aurora, CO 80045, USA.
Joaquin M EspinosaLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA; Department of Pharmacology, University of Colorado Anschutz, Aurora, CO 80045, USA.
Kelly D SullivanLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora, CO 80045, USA; RNA Bioscience Initiative, University of Colorado Anschutz, Aurora, CO 80045, USA; Department of Pediatrics, Section of Developmental Biology, University of Colorado Anschutz, Aurora, CO 80045, USA. Electronic address: kelly.d.sullivan@cuanschutz.edu.

Funding

The INCLUDE Project Down Syndrome Biorepository (DS-Biorepository)U24AG092191 · NIA · UNIVERSITY OF COLORADO DENVER · PI Joaquin M. Espinosa, Matthew D Galbraith · 2024 to 2026
$15.8M
Understanding Down Syndrome as an InterferonopathyR01AI150305 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ESPINOSA, JOAQUIN M. · 2019 to 2020
$3.5M
Trisomy 21 Model AtlasR24OD035579 · OD · UNIVERSITY OF COLORADO DENVER · PI Joaquin M. Espinosa, Matthew D Galbraith · 2023 to 2026
$3.0M
Pre-clinical assessment of JAK inhibitors to ameliorate cytokine storms in Down syndromeR01AI145988 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SULLIVAN, KELLY D. · 2019 to 2023
$2.2M
NIAID NIH HHS R01 AI145988NIAID NIH HHS R01 AI150305NIA NIH HHS U24 AG092191NIH HHS R24 OD035579
6 · The paper itself

Abstract

Trisomy 21 (T21) gives rise to Down syndrome (DS), the most commonly occurring chromosomal abnormality in humans. T21 affects nearly every organ and tissue system in the body, predisposing individuals with DS to congenital heart defects, autoimmunity, and Alzheimer's disease, among other co-occurring conditions. Here, using multi-omic analysis of plasma from more than 400 people, we report broad metabolic changes in the population with DS typified by increased bile acid levels and protein signatures of liver dysfunction. In a mouse model of DS, we demonstrate conservation of perturbed bile acid metabolism accompanied by liver pathology. Bulk RNA sequencing revealed widespread impacts of the Dp16 model on hepatic metabolism and inflammation, while single-cell transcriptomics highlighted cell types associated with these observations. Modulation of dietary fat profoundly impacted gene expression, bile acids, and liver pathology. Overall, these data represent evidence for altered hepatic metabolism in DS that could be modulated by diet.

Indexed as

Down SyndromeLiverAnimalsBile Acids and SaltsDisease Models, AnimalFemaleHumansMaleMiceBile Acids and Saltsbile acidsCP: MetabolismCP: Stem cell researchDown syndromelivermetabolism

Identifiers

PMID41538324
PMCPMC12977193

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.